BBLG

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended January 31, 2010, for AFH Acquisition X, Inc. (Note: The input metadata references "Bone Biologics Corp," but the filing text explicitly identifies the registrant as AFH Acquisition X, Inc.). The company is a Delaware corporation classified as a shell company and a development stage enterprise. Its primary business purpose is to seek a business combination through the acquisition or merger with an existing company. As of the filing date, the company has no specific business plan, no active operations, and is not conducting negotiations with any target business.

Key Financial Metrics

Debt and Liquidity: The company has no cash on hand. Liabilities consist of $6,468 in accrued expenses and $14,770 due to the parent company (AFH Holding & Advisory, LLC). There are no repayment terms specified for the amount due to the parent.

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss for the three months ended January 31, 2010, was $787, a significant decrease from the $5,714 loss reported for the same period in 2009. This reduction is attributed to lower professional service fees incurred in the current quarter.
• Cash Position: Cash and cash equivalents remained at $0 for the current quarter, consistent with the end of the prior fiscal year (October 31, 2009), though the company held $16 in cash at the end of the prior quarter (January 31, 2009).
• Liabilities: Total liabilities increased slightly from $20,451 (Oct 31, 2009) to $21,238 (Jan 31, 2010), driven by an increase in accrued expenses.

Outlook, Risks, and Management Commentary

Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has incurred recurring losses and has no revenues. Continued existence is dependent on raising capital or successfully acquiring a marketable company.

Future Operations: The company anticipates incurring costs related to filing Exchange Act reports and investigating potential acquisitions over the next 12 months. Management intends to fund these costs through treasury funds (currently $0), deferral of fees, or loans/investments from stockholders and management.

Risks:

• Blank Check Status: As a "blank check" company, there is no assurance the company will locate or negotiate with a target business.
• Liquidity Risk: The company has no cash and relies entirely on related parties for funding. If funding is unavailable, the company may not implement its plan of operations.
• Target Risk: Any acquired target may be financially unstable or in early development stages, inheriting significant operational risks.

Unusual Items: The filing contains no unusual items; expenses are limited to standard organizational, legal, and professional fees.

Investor Verification Checklist

• Identity Discrepancy: Verify the relationship between the metadata name "Bone Biologics Corp" and the filing registrant "AFH Acquisition X, Inc."
• Capital Adequacy: Confirm the source of funding for upcoming operational costs, given the company has $0 cash and $21,238 in liabilities.
• Parent Company Support: Assess the willingness and ability of the parent company (AFH Holding & Advisory, LLC) to continue advancing funds, as the company owes them $14,770 with no repayment terms.
• Acquisition Progress: Verify if any negotiations with target companies have commenced since the filing date, as none were active as of January 31, 2010.